.
Michael Mithoefer, M.D., began collaborating with MAPS in 2000 on the first U.S. Phase 2 clinical trial of MDMA-assisted psychotherapy.
He has since conducted two of the six MAPS-sponsored Phase 2 clinical trials testing MDMA-Assisted Psychotherapy for PTSD, as well a study providing MDMA-assisted sessions for therapists who have completed the MAPS-sponsored MDMA Therapy Training Program, and a pilot study treating couples with MDMA-Assisted Psychotherapy combined with Cognitive-Behavioural Conjoint Therapy.
He is now Senior Medical Director for Medical Affairs, Training and Supervision at MAPS Public Benefit Corporation (MAPS PBC). He is a Grof-certified Holotropic Breathwork Facilitator, is trained in EMDR and Internal Family Systems Therapy, and has nearly 30 years of experience treating trauma patients.
MAIN OFFICE
Suite 200, 366 Bay St,
Toronto, Ontario, M5H 4B2, Canada
UK OFFICE
1 Regent Street,
Bristol, BS8 4HW, United Kingdom
© 2021 Awakn Life Sciences Inc | Privacy Policy | Appropriate Use Policy